



# DERMAGNOSTIX

Dermagnostix is a medtech company that develops, manufactures and markets fully automated, molecular diagnostic tests for unmet clinical needs in dermatology.

With PsorX-LabDisk (CE-IVD), Dermagnostix launches the first molecular test to support the differential diagnosis of psoriasis and eczema. PsorX can be performed by minimally trained users in a self-contained mini-lab, at the point-of-need.



## **Problem:**

An estimated 20-25% of the world's population suffers from an inflammatory skin disease. Due to the lack of objective diagnostic tools and substantial overlap in clinical and histopathologic presentation, up to 50% of patients are misdiagnosed. New systemic treatments for skin diseases such as psoriasis and eczema are fundamentally different. Therefore, modern biologics and small-molecule inhibitors tailored for either psoriasis or eczema may fall short of their therapeutic potential or even cause severe side-effects.

## **Dermagnostix' solution:**

Dermagnostix offers molecular diagnostic solutions to meet the need for personalized medicine. We are the first company to combine both innovative proprietary biomarkers from our AI based research pipeline and a highly versatile microfluidics lab-on-a-disk system. Our modular system allows for prototype development of pre-selected molecular classifiers in short time. The LabDisk-Analyzer and LabDisk platform enables both cost-efficient and quick production cycles to implement complex diagnostics. Dermagnostix sells the LabDisks (single use test cartridges), as well as the LabDisk-Analyzer (complete lab instrument) to pathologists, dermatologists, and clinical research organizations.

Our first gene-expression-based test, PsorX, distinguishes psoriasis from eczema on molecular level. Novel LabDisk tests in our biomarker pipeline address clinical questions to provide comprehensive diagnostics and theranostics in dermatology. There is a need for timely and cost-efficient identification of molecular biomarkers in research and clinical development to inform target selection, drug candidate selection and understand the mechanism of action. Our pipeline of molecular tests will bring innovative solutions to challenges in clinical dermatology and clinical research. Simply. And at the point-of-need.

- PatternX
- PredX
- Mycosis fungoides (PsorX 2.0)

**Our mission:** At Dermagnostix, we build leading innovative molecular diagnostic solutions at scale and point-of-need for diagnostic laboratories, dermatologists and academic, pharmaceutical and clinical research organizations. With our quick, precise and automated molecular tests, we provide clinicians the objective information they need to improve patient outcomes through the integration of precision, dermatology and personalized medicine.

**Our vision:** Moving diagnostic frontiers in dermatology

**Founding year:** 2021 **Explore more:** [www.dermagnostix.com](http://www.dermagnostix.com) **Get in touch:** [info@dermagnostix.com](mailto:info@dermagnostix.com)

